Home > Products > SNPs > PACA (Pancreatic Cancer)


(Pancreatic Cancer) 

qPCR SNP Detection Kit

PACA (Pancreatic Cancer) qPCR SNP Detection Kit


Analysed genes are responsible for production of enzymes in the pancreas. Abnormalities in the production of these enzymes result in inflammation of the pancreas, which over time can lead to cancer of the pancreas.




Pancreatic Cancer




rs111033565, rs17107315


2 × Nuclease-Free Water
2 × 2xSNP MasterMix
2 × Oligos Set
2 × Positive Control Set


100 rxns


-25°C to -15°C


More Information

Did you know...?

Pancreatic cancer is seventh among cause of death from cancer. This type of cancer is highly lethal and is still characterised by low 5-year survival rate. Pancreatic cancer is more frequent in developed countries. It was estimated that 111,500 people will die from pancreatic cancer in Europe by 2025. Globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040.

What may happen?

PRSS1 and SPINK1 genes are associated with an increased risk of pancreatic cancer. The PRSS1 gene encodes trypsinogen, a precursor to the digestive enzyme - trypsin, which is responsible for proper protein digestion in the body. The SPINK1 gene encodes a pancreatic secretory trypsin inhibitor (PSTI). The inhibitor disables approximately 20% of intra-pancreatic trypsin activity. Mutations in these genes cause loss of trypsinogen and PSTI function. Without this function, the pancreas is exposed to repeated damage that may lead to the development of pancreatic inflammation and, consequently, the neoplastic process.You should be vigilant if you observe: nausea, vomiting, weight loss and lack of appetite, diarrhoea, depression, recurrent pancreatitis, subcutaneous nodules, abdominal pain, located in the upper abdominal region (epigastric), often radiating to the spine.

How the test is performed?

The PRSS1 and SPINK1 genes are fragments of DNA containing instructions for building proteins that contribute to the development of pancreatic cancer. The test performed concerned specific positions in both genes, where changes (mutations) can occur. The real-time PCR method is used for gene analysis, which allows for fast determination of the patient’s genetic variant and thus the risk of developing pancreatic cancer.

How will the client benefit?

The preparation of the reaction mixture is simple and requires a small amount of reagents and test material. An additional advantage is the same thermal cycling profile for both genes, which allows for simultaneous analysis using the same device and obtaining results in a short time. The ease of interpretation of the results based on matrix in the IFU of the product allows for the efficient determination of the patient’s genotype and the risk of developing the disease. The patient will receive a result with a precise determination of his genotype along with recommendations.

Why is it worth doing a genetic test?

Professional service and a report with a comprehensive explanation of the result and recommendations will encourage the patient to use other genetic tests. This is particularly important in the case of diseases such as pancreatic cancer, in which early diagnosis gives a chance of survival.

What can be done after the test result?

In the case of an unfavorable variant of the gene, it is important to follow the recommendations and consult a doctor. It should be remembered that a normal genotype does not exclude the disease. The great potential of genetic testing makes it possible to predict many diseases and gives a chance to take action to improve health.